An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States

References

• Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm 2009;66:1711-17
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013;1:423-7
   Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011;46:709-18
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52:e56-93
   PubMed Web of Science ®Google Scholar
• Merck & Co. Inc. Noxafil (posaconazole) oral suspension [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc, 2013
   Google Scholar
• Merck Sharp & Dohme Limited. Noxafil (posaconazole) oral suspension [summary of product characteristics]. Hertfordshire, UK: Merck Sharp & Dohme Limited 2013
   Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-59
   PubMed Web of Science ®Google Scholar
• Peterson L, Ostermann J, Rieger H. Posaconazole prophylaxis–impact on incidence of invasive fungal disease and antifungal treatment in haematological patients. Mycoses 2013;56:651-8
   Google Scholar
• Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis 2012;55:1515-21
   PubMed Web of Science ®Google Scholar
• Girmenia C, Frustaci AM, Gentile G, et al. Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica 2012;97:560-7
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012;97:459-63
   PubMed Web of Science ®Google Scholar
• Egerer G, Geist MJ. Posaconazole prophylaxis in patients with acute myelogenous leukaemia–results from an observational study. Mycoses 2011;54(1 Suppl):7-11
   Google Scholar
• Hahn J, Stifel F, Reichle A, et al. Clinical experience with posaconazole prophylaxis–a retrospective analysis in a haematological unit. Mycoses 2011;54(1 Suppl):12-16
   Google Scholar
• Pagano L, Caira M. The role of primary antifungal prophylaxis in patients with haematological malignancies. Clin Microbiol Infect 2014;20(Suppl 6):19-26
   Google Scholar
• Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010;65:1466-71
   PubMed Web of Science ®Google Scholar
• Michallet M, Sobh M, Morisset S, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol 2011;49:681-7
   PubMed Web of Science ®Google Scholar
• Frost M, O’Sullivan A, Morrisey O, et al. Cost effectiveness of antifungal prophylaxis with posaconazole versus standard azole therapy in the prevention of invasive fungal infections (IFIs) among high risk haematology patients in Australia. 6th Annual Health Technology Assessment International Meeting. Singapore: Annals of the Academy of Medicine Singapore, 2009
   Google Scholar
• Papadopoulos G, Hunt S, Prasad M. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study. J Med Econ 2013;16:374-80
   PubMedGoogle Scholar
• Athanasakis K, Petrakis I, Kyriopoulos J. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece. J Med Econ 2013;16:678-84
   PubMedGoogle Scholar
• Tahami Monfared AA, O’Sullivan AK, Rotstein C, et al. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol 2012;23:59-64
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. PharmacoEconomics 2011;29:251-68
   PubMed Web of Science ®Google Scholar
• Rely K, Alexandre PK, Escudero GS. Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico. Value Health 2011;14(5 Suppl 1):S39-42
   Google Scholar
• Michallet M, Gangneux JP, Lafuma A, et al. Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system. J Med Econ 2011;14:28-35
   PubMedGoogle Scholar
• Greiner RA, Meier Y, Papadopoulos G, et al. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. Oncology 2010;78:172-80
   PubMed Web of Science ®Google Scholar
• Kolbin AS, Klimko N, Koroleva O. Cost-effect analysis of the use of posaconazole for prophylaxis of invasive mycoses compared to fluconazole and itraconazole in patients with pronounced neutropenia [PSY32]. Value Health 2010;13(3):A211
   Google Scholar
• Suchankova E, Dolezal T, Simonova J. Cost-effectiveness of antifungal prophylaxis with posaconazole versus standard azole therapy in the prevention of invasive fungal infections among high risk haematology patients in Czech Republic [PSY27]. Value Health 2009;12(7):A380
   Google Scholar
• O’Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health 2009;12:666-73
   PubMed Web of Science ®Google Scholar
• Rely K, Pierre KA, Salinas EG. Cost utility of posaconazole versus fluconazole/itraconazole therapy in the prophylaxis against invasive fungal infections among high-risk neutropenic patients in Mexico [PCN74]. Value Health 2009;12:A50
   Google Scholar
• Kim Y, Lee D, Jun S, et al. Cost-effectiveness analysis of posaconazole for prophylaxis in patients with neutropenia in South Korea [PIN 16]. Value Health 2009;12(3):A112
   Google Scholar
• Stam WB, O'Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008;81:467-74
   PubMed Web of Science ®Google Scholar
• Thalheimer M, Cornely OA, Hoppe-Tichy T, et al. Pharmaco-economic analysis of posaconazole versus standard azole prophylaxis in high-risk neutropenic AML/MDS patients in Germany [P1031 plus poster]. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona; 2008
   Google Scholar
• Grau S, de la Camara R, Sabater FJ, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain. BMC Infect Dis 2012;12:83
   Google Scholar
• Maertens M, Aoun M, Bron D, et al. Cost-effectiveness of posaconazole (Noxafil) versus standard azole therapy in the prevention of invasive fungal infections among high-risk neutropenic patients in Belguim [poster]. 10th International Symposium on Febrile Neutropenia, Brussels; 2008
   Google Scholar
• Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008;65:2237-43
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. Support Care Cancer 2011;19:1807-13
   PubMed Web of Science ®Google Scholar
• Merck & Co. Inc. Noxafil (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc., 2014
   Google Scholar
• Krishna G, Ma L, Martinho M, et al. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother 2012;56:4196-201
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Martinho M, et al. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemoth 2012;67:2725-30
   PubMed Web of Science ®Google Scholar
• Howlader N NA, Krapcho M, Garshell J, et al, eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute, 2014
   Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65
   PubMed Web of Science ®Google Scholar
• Coin News Media Group LLC. US Inflation Calculator. San Antonio, TX: Coin News Media Group LLC. 2014 [cited July 2014]; Available from: http://www.usinflationcalculator.com/
   Google Scholar
• Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997;33:52-77
   PubMed Web of Science ®Google Scholar
• Pfizer I. DIFLUCAN (Fluconazole Tablets) (Fluconazole for Oral Suspension) Labeling. New York, NY: Roerig, a Division of Pfizer Inc., 2014
   Google Scholar
• Christensen KJ, Gubbins PO, Gurley BJ, et al. Relative bioavailability of itraconazole from an extemporaneously prepared suspension and from the marketed capsules. Am J Health Syst Pharm 1998;55:261-5
   Google Scholar
• Janssen Pharmaceuticals I. Sporanox® Capsule Product Information. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2014
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Garey KW, Aitken S, Dima-Ala A, et al. Echinocandin use in hospitalized patients; a multi-institutional study. Am J Med Sci. (Accepted November 20, 2014)
   Google Scholar